
==== Front
Turk J Obstet Gynecol
Turk J Obstet Gynecol
TJOG
Turkish Journal of Obstetrics and Gynecology
2149-9322
2149-9330
Galenos Publishing

38440966
10.4274/tjod.galenos.2024.92597
64615
Clinical Investigation
A novel predictive model of lymphovascular space invasion in early-stage endometrial cancer
Taşkum İbrahim 1https://orcid.org/0000-0001-5260-2087

Bademkıran Muhammed Hanifi 2https://orcid.org/0000-0002-9350-582X

Çetin Furkan 3https://orcid.org/0000-0001-6868-0434

Sucu Seyhun 2*https://orcid.org/0000-0001-6821-4070

Yergin Erkan 1https://orcid.org/0000-0002-3637-136X

Balat Özcan 2https://orcid.org/0000-0002-9158-0009

Özkaya Halil 3https://orcid.org/0000-0003-2331-6414

Uzun Evren 4https://orcid.org/0000-0001-8213-4747

1 Gaziantep City Hospital, Clinic of Obstetrics and Gynecology, Gaziantep, Turkey
2 Gaziantep University Faculty of Medicine, Department of Obstetrics and Gynecology, Gaziantep, Turkey
3 Abdulkadir Yüksel State Hospital, Clinic of Obstetrics and Gynecology, Gaziantep, Turkey
4 Gaziantep University Faculty of Medicine, Department of Medical Pathology, Gaziantep, Turkey
* Address for Correspondence: Gaziantep University Faculty of Medicine, Department of Obstetrics and Gynecology, Gaziantep, Turkey Phone: +90 532 624 00 72 E-mail:seyhunsucu80@gmail.com
3 2024
4 3 2024
21 1 3742
13 1 2024
29 1 2024
Copyright© 2024 The Author. Published by Galenos Publishing House on behalf of Turkish Society of Obstetrics and Gynecology.
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the Creative Commons AttributionNonCommercial 4.0 International (CC BY-NC 4.0) License.
Objective:

To predict lymphovascular space invasion (LVSI) positivity in early-stage (stage 1-2) endometrial cancer (EC) using a predictive model with prognostic factors of EC.

Materials and Methods:

We included 461 patients who underwent total hysterectomy and bilateral salpingo-oophorectomy with pelvic-paraaortic lymphadenectomy as the primary treatment for presumed early-stage EC at our clinic between 2010 and 2020. Moreover, all surgical specimens were examined histopathologically for the positivity or negativity of LVSI, and the patients were divided into two groups based on these pathologic outcomes. Age, menopausal status, histological type (type 1-2), histological grade (grades 1-2-3), depth of myometrial invasion, and peritoneal cytology results were recorded and analyzed as clinicopathological and demographic characteristics of the patients. The Loess algorithm determined the relationship between the observed and predicted outcomes. The distinction between the algorithms was evaluated by calculating the C-index.

Results:

LVSI positivity was significantly associated with advanced age, menopause, type 2 EC, advanced histological grade, malignant peritoneal cytology, cervical involvement, and a tumor exceeding 50% of the myometrial depth (p<0.001, respectively). Remarkably, LVSI was most strongly associated with three explanatory variables: 1- More than 50% myometrial invasion [odds ratio (OR): 3.78; 95% confidence interval (CI): 1.80-7.60], 2- Advanced histological grade [OR=1.98 (1.20-3.20) 95% CI], 3- Malignant peritoneal cytology [OR= 3.06 (1.40-6.30) 95% CI]. The penalized maximum likelihood estimation model correctly classified 87% of the included patients (C-index: 0.876).

Conclusion:

Our predictive model may help predict LVSI based on different prognostic factors. The prognostic factors included in the nomogram were significantly associated with LVSI, particularly myometrial invasion depth of more than 50%, advanced histological grade, and malignant peritoneal cytology.

Endometrial cancer
lymph node metastasis
lymphovascular space invasion
predictive model
==== Body
pmcPRECIS: Predicting lymphovascular space invasion in early-stage endometrial cancer.

Introduction

Endometrial cancer (EC) is the most common malignancy of the female genital tract in developed countries, and it is the second most common malignancy after cervical cancer in developing countries(1). In some patients with EC, advanced age is mainly associated with higher treatment failure rates and poor survival rates(2). Patients with EC are classically present with postmenopausal bleeding, defined as bleeding that occurs at least a year after the natural cessation of menstrual cycles(3). The current literature offers strong evidence regarding endometrial sampling performed using Pipelle biopsy or conventional dilation and curettage as the most accurate method for EC diagnosis(4). Staging and treatment planning for EC are generally based on the International Federation of Gynecology and Obstetrics (FIGO) guidelines. Treatment is primarily surgical, and total hysterectomy and bilateral salpingo-oophorectomy are the standard surgical approach(5); nevertheless, the decision to perform pelvic or additional paraaortic lymphadenectomy for all patients remains questionable. Factors such as advanced age, advanced surgical stage, high-grade tumor, myometrial invasion, lymphovascular space invasion (LVSI), large tumor size, and malignant peritoneal cytology have been reported as poor prognostic factors for EC(6). EC classification follows the FIGO guidelines, which use a three-step process to categorize the mucinous and endometrioid types according to their histological grade. However, clear, serous, squamous, undifferentiated, and small-cell ECs are not graded or considered high grade (grade 3)(7). As the depth of invasion into the myometrium increases, so does the risk of lymphatic system invasion, extrauterine involvement, and recurrence, all of which can negatively impact prognosis(8). LVSI is an independent risk factor for lymph node metastasis and disease recurrence(9). EC staging now includes LVSI as an essential factor(10). Adjuvant therapy should be considered for stage I EC patients with lymph node evaluation because of the significant prediction of LVSI for nodal recurrence and poorer overall survival(11).

In cases of EC, it has been reported that approximately 4.4% of individuals who undergo surgical staging characterize malignant peritoneal cytology(12). However, peritoneal cytology is excluded from the current FIGO guidelines(10).

This study aimed to develop a new predictive model incorporating various prognostic factors to determine the likelihood of LVSI positivity in patients with early-stage EC. Moreover, the aim of this study is to provide clinical risk assessment counseling by using a nomogram with parameters that predict LVSI.

Materials and Methods

The Gaziantep University Faculty of Medicine Clinical Research and Ethics Committee approved this study (ethical approval no: 2022/258, date: 31.08.2022). In addition, this retrospective study was designed to follow the current guidelines of the World Medical Association’s Declaration of Helsinki.

Patient Selection and Data Collection

The High-Security Hospital Data System identified 601 patients who underwent surgery for EC between 2010 and 2020 in the Department of Gynecology and Obstetrics of Gaziantep University Faculty of Medicine. Age, premenopausal or postmenopausal status, histopathological EC type (type 1 or 2), histological grade of EC (grade 1, 2, and 3), and myometrial invasion positivity (whether the tumor exceeded ½ of the myometrium) of the included patients were recorded. Further, pathology results regarding cervical involvement of EC, malignant peritoneal cytology positivity, and pelvic-paraaortic lymph node positivity were documented, and these outcomes were recorded. Patients with missing recorded data for inclusion criteria and whose final pathology result was reported as advanced-stage EC were excluded from the study. According to the final pathology results that specified early-stage (stage 1-2) EC diagnosis(10), 461 patients were included in the study.

Biostatistics

In this study, numerical variables were presented using the median (interquartile range), while categorical variables were presented as “n, (%)”. Continuous variables were compared using Student’s t-test for normally distributed data and the Mann-Whitney U test for non-normally distributed data. Categorical variables were analyzed using the chi-square test (χ2). The data were summarized with descriptive statistics, including frequency, percentage (%), and mean ± standard deviation. A significance level of p-value 0.05 was considered in this study.

Candidate Predictors and Statistical Modeling

This study examined several factors as potential predictors of LVSI positivity in early-stage EC. This predictive model was designed with candidate predictors that met the necessary conditions and were selected based on previous research(13). The seven candidate predictors for the final predictive model included age, menopause status, histological type of EC, degree of myometrial invasion, malignant peritoneal cytology positivity, cervical involvement of EC, and histological grade of EC. No variables with very low or very high frequencies were included in the model.

This model’s predicted outcome was prescribed as LVSI positivity in early-stage EC. The Loess algorithm examined the correlation between observed and predicted values. Model discrimination was estimated by calculating the C-index. A 40-bootstrap replication was used for internal validation of the expected model. Predictive model validation consisted of discrimination (Harrell’s C-index) and calibration (calibration plots) using the validation set. In line with previous research(14), this study assumed that a >0.75 C-index value represented relatively good discrimination. On the basis of this predictive model, a nomogram was created. All statistical analyses were performed using R version 3.5.1 (R Statistical Software, Institute for Statistics and Mathematics, Vienna, Austria).

Results

The baseline clinical characteristics of the study groups and the comparison of all prognostic factors in patients with and without LVSI are detailed in “Table 1”. LVSI positivity was not detected in 396 of 461 patients in the study. However, LVSI was positive in the pathology results of 65 patients. LVSI positivity was strongly associated with a myometrium exceeding 1/2, advanced histological grade, and malignant peritoneal cytology. Of the 65 patients with LVSI positivity, 18 (27.7%) had tumor invasion not exceeding ½ myometrium. Similarly, in 47 (72.3%) of LVSI positivity patients, the tumor did not invade beyond ½ myometrial depth. Tumor invasion did not exceed ½ myometrium in 323 (81.6%) of 396 patients without LVSI positivity. In the remaining 73 (18.4%) of patients without LVSI, the tumor extended beyond ½ myometrial depth. The results showed a significant association between patients with myometrial depth exceeding ½ and patients with LVSI positivity [odds ratio (OR): 3.78 (1.80-7.60) 95% confidence interval (CI)]. Of the 65 patients with LVSI, 7 (10.8%) had grade 1, 18 (27.7%) had grade 2, and 40 (61.5%) had grade 3. In comparison, the findings for the 396 patients without LVSI were as follows: 156 (39.4%) had grade 1, 188 (47.5%) had grade 2, and 52 (13.1%) had grade 3. These results suggest that histological grading is an important prognostic indicator for patients with LVSI positivity [1.98 (1.20-3.20) 95% CI]. Upon analyzing the peritoneal cytology results of 65 patients with LVSI positivity, it was found that 27 (41.5%) had benign results and 38 (58.5%) had malignant results. In contrast, when the peritoneal cytology results of 396 patients without LVSI were examined, 351 (88.6%) had benign results and 45 (11.4%) had malignant results. Furthermore, a significant correlation was found between patients with malignant peritoneal cytology results and LVSI positivity (OR: 3.06 [1.40-6.30] 95% CI). “Table 2” presents and summarizes predictive model’s ORs and CIs. A predictive model based on these candidate variables was created, with a penalized maximum likelihood estimation model correctly classifying 87% of participants. The calibration between the predicted and observed results was acceptable. A plot of the observed and expected results for LVSI positivity in early-stage EC is illustrated in “Figure 1”, and a nomogram based on the final refined predictive with the candidate variables is shown in “Figure 2”.

Discussion

In this study, a predictive model was created to predict the presence of LVSI in early-stage EC. Accordingly, LVSI positivity was strongly associated with myometrial invasion of more than ½, advanced histological grade, and malignant peritoneal cytology. In addition, LVSI positivity was related to the non-endometrioid type of EC, cervical stromal involvement, and post-menopausal period, according to the predictive model.

There is a discussion regarding the validity of advanced age as an independent prognostic factor; however, it is common for patients over 65 years of age to experience deep myometrial invasion, higher tumor grade, and advanced stage(15). In the meta-analysis research by Clarke et al.(16), it was reported that early diagnosis strategies focusing on women with postmenopausal bleeding can detect 90% of EC; however, it was concluded that several women with postmenopausal bleeding may not be diagnosed with EC, remarkably. The results of the present study indicate that LVSI positivity is more prevalent in menopausal patients who have early-stage EC, signifying a robust correlation with advanced age (p=0.006); nevertheless, there was a low level of association between age and LVSI positivity [OR: 1 (0.97-1.05) 95% CI].

Ayhan et al.(17) analyzed 912 low-risk EC patients, and LVSI positivity was detected in 53 (5.8%) patients. Their study reported that LVSI positivity was significantly associated with grade 2 EC (p<0.001), the presence of deep myometrial invasion (p=0.003), and large tumor size (p=0.005), according to the postoperative pathology results. Therefore, the grade of the tumor as a prediction factor was included in our predictive model. In a study by Doghri et al.(18), 62 patients with EC were analyzed to determine the significance of depth myometrial invasion as a prognostic factor. Consequently, their study showed that advanced invasion of the myometrium was associated with a risk of pelvic and para-aortic lymph node metastasis, which is indicated by high-grade EC. In parallel with the previous studies, the present study found a strong and significant correlation between LVSI positivity and exceeding 1-2 myometrium [OR: 3.78 (1.80-7.60) 95% CI].

In the study by Malik et al.(19), the researchers reported that approximately 75-80% of 180 patients had type 1 EC and highlighted that many patients in the early stages showed a favorable prognosis; moreover, they noted that the 5-year survival rate in patients without lymph node involvement was 96%, compared with 67% for those with involvement. In the present study, in which we compared the prognostic factors determined in early-stage EC cases, the histological type of EC showed a significant difference in LVSI positivity [OR: 1.72 (0.78-3.78) 95% CI].

Histological grade has been identified as an independent predictor of recurrence in EC(20). Additionally, in the PORTEC 1 trial, the results of multivariate analysis confirmed the significance of grade 3 disease for locoregional recurrence(21). The histological high grade (grade 3) and LVSI positivity were associated with a high statistical significance in the present study [OR: 1.98 (1.20-3.20) 95% CI].

In the staging system for EC, malignant peritoneal cytology is no longer sufficient to upstage the T stage, according to FIGO(10). In a study by Scott et al.(22), malignant peritoneal cytology was not significantly associated with cure and overall survival in low- and intermediate-risk EC patients. In EC, malignant peritoneal cytology refers to tumor cells in a peritoneal fluid sample taken during surgery. This was once a component of the EC staging criteria but is no longer included in the current revision. However, many associations and organizations still recommend cytological sampling in EC surgery(23). This study found a significant correlation between malignant peritoneal cytology and LVSI positivity [OR: 3.06 (1.40-6.30) 95% CI].

In stage 2 early-stage EC, the tumor involves the cervix but not beyond the serosa, and there is no endocervical gland involvement(10). In a study by Toprak et al.(24), a primary tumor diameter of at least 3 cm and an LVSI of at least 50% were determined to be independent markers of cervical involvement in women with EC. Therefore, tumor diameter was not included in our predictive model; additionally, there was no endocervical gland involvement in the patients included, and the tumor did not exceed the serosa. In the present study concerning patients with early-stage EC, a noteworthy association was determined between cervical stromal involvement of EC and LVSI positivity [OR: 1.78 (0.85-3.71) 95% CI].

Study Limitations

It is essential to acknowledge that the predictive model we developed has some limitations that need to be considered. Specifically, the study was conducted retrospectively, and multiple pathologists were involved in evaluating the pathology results. Additionally, the research was conducted in a single-center setting, limiting the generalizability of our findings.

Conclusion

Age, menopausal status, histological type, tumor grade, degree of myometrial invasion, peritoneal cytology, and cervical involvement may predict LVSI positivity in early-stage EC. Clinical consultancy services can be provided by evaluating risk factors using nomograms based on predictions.

Table 1 Demographic, histopathological, and prognostic factors

Table 2 Predicting LVSI risk with prognostic factors

Figure 1 Calibration plot of observed results and predicted outcome to predict LVSI with prognostic factors

LVSI: Lymphovascular space invasion

Figure 2 A nomogram based on the final refined estimates with candidate variables of early-stage EC to predict LVSI positivity

LVSI: Lymphovascular space invasion, EC: Endometrial cancer, Peritoneal Cytology Positive: Malign Peritoneal Cytology

Ethics

Ethics Committee Approval: The Gaziantep University Faculty of Medicine Clinical Research and Ethics Committee approved this study (ethical approval no: 2022/258, date: 31.08.2022).

Informed Consent: All patients who participated in the study signed a consent form.

Authorship Contributions

Surgical and Medical Practices: İ.T., M.H.B., F.Ç., S.S., E.Y., Ö.B., Concept: İ.T., M.H.B., E.Y., Ö.B., Design: İ.T., M.H.B., H.Ö., Data Collection or Processing: İ.T., S.S., H.Ö., E.U., Analysis or Interpretation: İ.T., E.Y., Ö.B., H.Ö., E.U., Literature Search: İ.T., H.Ö., E.U., Writing: İ.T., M.H.B., F.Ç., E.U.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.
==== Refs
References

1 Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A et al Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 2021 71 209 49 33538338
2 Colombo N Creutzberg C Amant F Bosse T González-Martín A Ledermann J et al ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up Int J Gynecol Cancer 2016 26 2 30 26645990
3 Sung S, Abramovitz A. Postmenopausal Bleeding. In: StatPearls. Treasure Island (FL): StatPearls Publishing. accessed September 18, 2022. [Internet] https://www.ncbi.nlm.nih.gov/books/NBK562188/
4 Sakna NA Elgendi M Salama MH Zeinhom A Labib S Nabhan AF Diagnostic accuracy of endometrial sampling tests for detecting endometrial cancer: a systematic review and meta-analysis BMJ Open 2023 13 e072124
5 Lau HY Chen MY Ke YM Chen JR Chen IH Liou WS et al Outcome of ovarian preservation during surgical treatment for endometrial cancer: A Taiwanese Gynecologic Oncology Group study Taiwan J Obstet Gynecol 2015 54 532 6 26522105
6 Oliver-Perez MR Padilla-Iserte P Arencibia-Sanchez O Martin- Arriscado C Muruzabal JC Diaz-Feijóo B et al Lymphovascular Space Invasion in Early-Stage Endometrial Cancer (LySEC): Patterns of Recurrence and Predictors. A Multicentre Retrospective Cohort Study of the Spain Gynecologic Oncology Group Cancers (Basel) 2023 15 2612 37174081
7 Amkreutz LCM Pijnenborg JMA Joosten DWL Mertens HJMM Van Kuijk SMJ Engelen MJA et al Contribution of cervical cytology in the diagnostic work-up of patients with endometrial cancer Cytopathol Off J Br Soc Clin Cytol 2018 29 63 70
8 Phelippeau J Canlorbe G Bendifallah S Naoura I Lefevre M Ballester M et al Preoperative diagnosis of tumor grade and type in endometrial cancer by pipelle sampling and hysteroscopy: Results of a French study Surg Oncol 2016 25 370 7 27916168
9 Restaino S Tortorella L Dinoi G Zannoni GF Baroni A Capasso I et al Semiquantitative evaluation of lymph-vascular space invasion in patients affected by endometrial cancer: Prognostic and clinical implications Eur J Cancer 2021 142 29 37 33217679
10 Berek JS Matias-Guiu X Creutzberg C Fotopoulou C Gaffney D Kehoe S et al Endometrial Cancer Staging Subcommittee, FIGO Women’s Cancer Committee. FIGO staging of endometrial cancer: 2023 Int J Gynaecol Obstet 2023 162 383 94 37337978
11 Veade AE Foote J Ehrisman J Broadwater G Davidson BA Lee PS et al Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma World J Surg Oncol 2019 17 80 31077193
12 Matsuo K Matsuzaki S Nusbaum DJ Machida H Nagase Y Grubbs BH et al Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer Eur J Cancer 2020 133 33 46 32434109
13 Wang J Li X Yang X Wang J Development and Validation of a Nomogram Based on Metabolic Risk Score for Assessing Lymphovascular Space Invasion in Patients with Endometrial Cancer Int J Environ Res Public Health 2022 19 15654 36497730
14 Hu Y You S Yang Z Cheng S Nomogram predicting survival of hepatocellular carcinoma with portal vein tumour thrombus after curative resection ANZ J Surg 2019 89 E20 5 30117625
15 Jolly S Vargas CE Kumar T Weiner SA Brabbins DS Chen PY et al The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation Gynecol Oncol 2006 103 87 93 16545441
16 Clarke MA Long BJ Del Mar Morillo A Arbyn M Bakkum-Gamez JN Wentzensen N Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis JAMA Intern Med 2018 178 1210 22 30083701
17 Ayhan A Şahin H Sari ME Yalçin I Haberal A Meydanli MM Prognostic significance of lymphovascular space invasion in low-risk endometrial cancer Int J Gynecol Cancer 2019 29 505 12 30665899
18 Doghri R Chaabouni S Houcine Y Charfi L Boujelbene N Driss M et al Evaluation of tumor-free distance and depth of myometrial invasion as prognostic factors in endometrial cancer Mol Clin Oncol 2018 9 87 91 29896403
19 Malik TY Chishti U Aziz AB Sheikh I Comparison of Risk Factors and Survival of Type 1 and Type II Endometrial Cancers Pak J Med Sci 2016 32 886 90 27648033
20 Bak SE Yoo JG Lee SJ Yoon JH Park DC Kim SI Prognostic significance of histological grade in low-risk endometrial cancer Int J Med Sci 2022 19 1875 8 36438921
21 Creutzberg CL Nout RA Lybeert ML Wárlám-Rodenhuis CC Jobsen JJ Mens JW et al; PORTEC Study Group Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma Int J Radiat Oncol Biol Phys 2011 81 e631 8 21640520
22 Scott SA van der Zanden C Cai E McGahan CE Kwon JS Prognostic significance of peritoneal cytology in low-intermediate risk endometrial cancer Gynecol Oncol 2017 145 262 8 28359690
23 Abu-Rustum N Yashar C Arend R Barber E Bradley K Brooks R et al Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw 2023 21 181 209 36791750
24 Toprak S Sahin EA Sahin H Tohma YA Yilmaz E Meydanli MM Risk factors for cervical stromal involvement in endometrioid-type endometrial cancer Int J Gynaecol Obstet 2021 153 51 5 33118165
